Dietary interventions for multiple sclerosis-related outcomes
Meta-analysisHumans
- Design
- Meta-analysis
- Subjects
- 30 randomised or controlled trials (41 articles) in adults with multiple sclerosis; palmitoylethanolamide was one of six 'other supplement' trials
- Dose used in the study
- Not stated in the abstract for palmitoylethanolamide
- Duration
- Not stated in the abstract
- What was measured
- Relapses, disability progression, MRI activity, serious adverse events and patient-reported outcomes for dietary interventions versus placebo or another intervention, with Cochrane methods and GRADE certainty
What the authors reported
This meta-analysis found:
- All 30 trials had at least one issue giving unknown or high risk of bias.
- For PUFA versus MUFA, the evidence on difference in relapses was very uncertain (RR 1.02, 95% CI 0.88 to 1.20; 3 trials, 217 participants, very low certainty).
- For antioxidants versus placebo, there may be little to no difference in relapses (RR 0.98, 0.59 to 1.64; 4 trials, 345 participants, low certainty).
- The authors say evidence is insufficient to determine whether antioxidants or other dietary interventions have any impact on MS-related outcomes. PEA is named in the abstract only as one of the other supplements studied.
Limits of this study
A Cochrane review; the abstract pools no PEA-specific results, so no PEA trial findings are reported here. Natalie Parks has consulted for and received funds from Biogen, EMD Serono, Roche and Sanofi Genzyme; Bradley Johnston received an institutional start-up grant.
Source
PubMed 32428983 · doi:10.1002/14651858.CD004192.pub4
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.